A Phase 1/2 interventional study of Galunisertib and Gemcitabine in Neoplasms, Neoplasm Metastasis and Pancreatic Cancer, sponsored by Eli Lilly and Company. Completed at 24 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-16.
Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Phase 1b: To determine the safe and tolerable dose of galunisertib in combination with gemcitabine in patients with solid malignancy
Phase 2a: To compare the overall survival (OS) of patients with Stage II to IV unresectable pancreatic cancer when treated with a combination of galunisertib and gemcitabine with that of gemcitabine plus placebo.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 170 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria: For both Phase 1b and Phase 2 (unless specified in the following), patients are eligible to be included in the study only if they meet all of the following criteria:
For Phase 1b:
For Phase 1b and Phase 2:
For Phase 2:
Exclusion Criteria: Patients will be excluded from the study if they meet any of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1: 40 mg Galunisertib was administered orally twice daily (BID) for 14 days followed by 14 days of rest (28 day cycle). Gemcitabine at a dose of 1000 mg/m\^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.
Drug: Galunisertib · Drug: Gemcitabine
Cohort 2: 80 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle). Gemcitabine at a dose of 1000 mg/m\^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.
Drug: Galunisertib · Drug: Gemcitabine
Cohort 3: 150 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle). Gemcitabine at a dose of 1000 mg/m\^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.
Drug: Galunisertib · Drug: Gemcitabine
Galunisertib recommended dose (300 mg) determined from phase 1, administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle). Gemcitabine at a dose of 1000 mg/m\^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.
Drug: Galunisertib · Drug: Gemcitabine
Placebo administered orally twice daily for 14 days followed 14 days of rest (28 day cycle). Gemcitabine at a dose of 1000 mg/m\^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.
Drug: Gemcitabine · Drug: Placebo
Administered orally
Also known as: LY2157299
Administered intravenously
Also known as: Gemzar, LY188011
Administered orally
Phase 1b: Recommended Phase 2 Dose
The recommended Phase 2 dose was the highest dose where less than 1/3 of participants experienced dose limiting toxicities (DLTs). The recommended dose was determined based on a review of overall toxicity, dose reductions, omissions, and pharmacokinetic information from Phase 1b.
Time frame: Time of first phase 1b dose until time of last phase 1b dose (up to 1 year)
Phase 2: Overall Survival (OS)
Overall survival is defined as the time from the date of randomization to the date of death from any cause. For each participant who is not known to have died as of the data-inclusion cut-off date for a particular analysis, overall survival duration was censored for that analysis at the date of last prior contact.
Time frame: Baseline to date of death from any cause (up to 2 years)
Phase 1b: Pharmacokinetics: Area Under the Concentration-Time Curve at Steady State From Time Zero to 24 Hours (AUC[0-24], ss) and Time Zero to Infinity (AUC[0-∞], ss)
AUC\[0-24h\] is a combined measure obtained from Day 14 at 0 hour (pre-dose), 0.5, 2,3, 6 hours post dose and morning doses from 24h and 48h to compute. AUC0-infinity will take 48h and extrapolation beyond this in addition to earlier time points to be calculated. All mentioned time points are used to calculate the two AUCs.
Time frame: Cycle 1 Days 14 (predose; 0.5, 2, 3, and 6 hours post dose), 24h (Days 15) and 48h (Days 16)
Phase 1b: Pharmacokinetics: Maximum Plasma Drug Concentration at Steady State (Cmax,ss)
Plasma samples for pharmacokinetic (PK) analysis were obtained on Day 14 at 0 hours (Pre-dose), 0.5, 2, 3, 6 hours post dose and morning doses from 24h and 48h. Cmax takes all time points post dose into account and one value is reported.
Time frame: Cycle 1 Days 14 (predose; 0.5, 2, 3, and 6 hours post dose), 24h (Days 15) and 48h (Days 16)
Phase 1b: Number of Participants With Tumor Response
Response was defined using RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1. Complete Response (CR) was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter (mm) and normalization of tumor marker level of non-target lesions; Partial Response (PR) was defined as having at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) was defined as having at least 20% increase in sum of longest diameter of target lesions and minimum 5 mm increase above nadir; Stable Disease (SD) was defined as small changes that did not meet above criteria.
Time frame: Baseline to end of Phase 1b (up to 1 year)
Phase 2: Progression Free Survival (PFS)
PFS is defined as the date of randomization to the first date of progression of disease or of death from any cause. For each participant who is not known to have died or to have had a progression of disease as of the data-inclusion cut-off date for a particular analysis, PFS will be censored at the date of last prior contact. PFS will be calculated and analyzed twice: (1) including clinical progressions of disease not based on lesion measurements, and (2) excluding clinical progressions. Progression Disease (PD) was defined as having at least a 25% increase in the sum of the longest diameter of target lesions.
Time frame: Baseline to first date of progressive disease or death due to any cause (up to 2 years)
Phase 2: Percentage Change From Baseline in Tumor Size (CTS)
Change in tumor size is defined as the maximum percent change from baseline in the sum of target lesions. Change was assessed in each participant using radiographic imaging.
Time frame: Baseline, end of Cycle 2 (up to 56 days)
Phase 2: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate[ORR])
Overall response rate is the best response of complete response (CR) or partial response (PR) as classified by the independent central review according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with at least 1 measurable lesion, multiplied by 100.
Time frame: Baseline to measured progressive disease (up to 2 years)
Phase 2: Population Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Time Zero to 24 Hours (AUC[0-24])
AUC\[0-24\] is a combined measure obtained from Day 14 at 0 hour (pre-dose), 0.5, 2,3, 6 hours post dose and morning doses from 24h and 48h to compute.
Time frame: Cycle 1 Days 14 (predose; 0.5, 2, 3, and 6 hours post dose), 24h (Days 15) and 48h (Days 16)
Phase 2: Population PK: Maximum Concentration (Cmax) of Galunisertib
Plasma samples for pharmacokinetic (PK) analysis were obtained on Day 14 at 0 hours (Pre-dose), 0.5, 2, 3, 6 hours post dose and morning doses from 24h and 48h. Cmax takes all time points post dose into account and one value is reported.
Time frame: Cycle 1 Days 14 (predose; 0.5, 2, 3, and 6 hours post dose), 24h (Days 15) and 48h (Days 16)
Phase 2: Change From Baseline in Brief Pain Inventory-short Form (BPI-sf) at Study Completion
The BPI-SF Pain Severity Subscale was a participant-rated questionnaire that measured the severity of pain. Severity scores could have ranged from 0 (no pain) to 10 (pain as bad as you can imagine) for questions that included assessing average pain in the past 24 hours.
Time frame: Baseline, study treatment completion (up to 1 year)
Phase 2: Change From Baseline in Carbohydrate Antigen 19.9 (CA19-9) Level at First Study Completion Follow-up
Carbohydrate antigen 19-9 (CA 19-9) is a modified Lewis(a) blood group antigen, and has been used as a tumor marker. The outcome measure is the median, minimum and maximum values from participants who had samples collected at baseline and at follow-up
Time frame: Baseline, study treatment completion after first follow up visit (up to 1 year)
| Milestone | Phase 1b: 80 mg (Milligrams) Galunisertib + Gemcitabine | Phase 1b: 160 mg Galunisertib + Gemcitabine | Phase 1b: 300 mg Galunisertib + Gemcitabine | Phase 2: 300 mg Galunisertib + Gemcitabine | Phase 2: Placebo + Gemcitabine |
|---|---|---|---|---|---|
| Started | 5 | 4 | 5 | 104 | 52 |
| Received at least one dose | 5 | 4 | 5 | 103 | 52 |
| Completed | 5 | 3 | 4 | 92 | 50 |
| Not completed | 0 | 1 | 1 | 12 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 10 | 2 |
The recommended Phase 2 dose was the highest dose where less than 1/3 of participants experienced dose limiting toxicities (DLTs). The recommended dose was determined based on a review of overall toxicity, dose reductions, omissions, and pharmacokinetic information from Phase 1b.
| milligrams (mg) | Phase 1b Participants |
|---|---|
| Phase 1b: Recommended Phase 2 Dose | 300 |
Overall survival is defined as the time from the date of randomization to the date of death from any cause. For each participant who is not known to have died as of the data-inclusion cut-off date for a particular analysis, overall survival duration was censored for that analysis at the date of last prior contact.
| Months | Phase 2: 300 mg Galunisertib + Gemcitabine | Phase 2: Placebo + Gemcitabine |
|---|---|---|
| Phase 2: Overall Survival (OS) | 8.9 (7.3 to 11.1) | 7.1 (5.8 to 9.0) |
AUC\[0-24h\] is a combined measure obtained from Day 14 at 0 hour (pre-dose), 0.5, 2,3, 6 hours post dose and morning doses from 24h and 48h to compute. AUC0-infinity will take 48h and extrapolation beyond this in addition to earlier time points to be calculated. All mentioned time points are used to calculate the two AUCs.
| nanogram*hour per milliliter (ng*h/mL) | Phase 1b: 80 mg Galunisertib + Gemcitabine | Phase 1b: 160 mg Galunisertib + Gemcitabine | Phase 1b: 300 mg Galunisertib + Gemcitabine |
|---|---|---|---|
| AUC(0-24) | 2530 ± 116 | NA ± NA | 9090 ± 27 |
| AUC(0-∞) | 2740 ± 117 | NA ± NA | 10600 ± 10 |
Plasma samples for pharmacokinetic (PK) analysis were obtained on Day 14 at 0 hours (Pre-dose), 0.5, 2, 3, 6 hours post dose and morning doses from 24h and 48h. Cmax takes all time points post dose into account and one value is reported.
| nanogram per milliliter (ng/mL) | Phase 1b: 80 mg Galunisertib + Gemcitabine | Phase 1b: 160 mg Galunisertib + Gemcitabine | Phase 1b: 300 mg Galunisertib + Gemcitabine |
|---|---|---|---|
| Phase 1b: Pharmacokinetics: Maximum Plasma Drug Concentration at Steady State (Cmax,ss) | 385 ± 101 | NA ± NA | 1050 ± 39 |
Response was defined using RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1. Complete Response (CR) was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter (mm) and normalization of tumor marker level of non-target lesions; Partial Response (PR) was defined as having at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) was defined as having at least 20% increase in sum of longest diameter of target lesions and minimum 5 mm increase above nadir; Stable Disease (SD) was defined as small changes that did not meet above criteria.
| Participants | Phase 1b: 80 mg Galunisertib + Gemcitabine | Phase 1b: 160 mg Galunisertib + Gemcitabine | Phase 1b: 300 mg Galunisertib + Gemcitabine |
|---|---|---|---|
| Progressive Disease (PD) | 3 | 1 | 2 |
| Stable Disease (SD) | 1 | 2 | 2 |
| Partial Response (PR) | 0 | 1 | 0 |
| Non-Complete Response/Non-Progressive Disease (NC) | 0 | 0 | 1 |
| Not Assessed (NA) | 1 | 0 | 0 |
PFS is defined as the date of randomization to the first date of progression of disease or of death from any cause. For each participant who is not known to have died or to have had a progression of disease as of the data-inclusion cut-off date for a particular analysis, PFS will be censored at the date of last prior contact. PFS will be calculated and analyzed twice: (1) including clinical progressions of disease not based on lesion measurements, and (2) excluding clinical progressions. Progression Disease (PD) was defined as having at least a 25% increase in the sum of the longest diameter of target lesions.
| Months | Phase 2: 300 mg Galunisertib + Gemcitabine | Phase 2: Placebo + Gemcitabine |
|---|---|---|
| Phase 2: Progression Free Survival (PFS) | 4.11 (2.66 to 5.42) | 2.86 (1.94 to 3.75) |
Change in tumor size is defined as the maximum percent change from baseline in the sum of target lesions. Change was assessed in each participant using radiographic imaging.
| Percent change in tumor size | Phase 2: 300 mg Galunisertib + Gemcitabine | Phase 2: Placebo + Gemcitabine |
|---|---|---|
| Independent Assessor 1 | 0.95 (0.90 to 1.01) | 0.92 (0.87 to 0.98) |
| Independent Assessor 2 | 1.03 (0.95 to 1.11) | 0.98 (0.92 to 1.05) |
Overall response rate is the best response of complete response (CR) or partial response (PR) as classified by the independent central review according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with at least 1 measurable lesion, multiplied by 100.
| Percentage of Participants | Phase 2: 300 mg Galunisertib + Gemcitabine | Phase 2: Placebo + Gemcitabine |
|---|---|---|
| Phase 2: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate[ORR]) | 10.6 (5.4 to 18.1) | 3.8 (0.5 to 13.2) |
AUC\[0-24\] is a combined measure obtained from Day 14 at 0 hour (pre-dose), 0.5, 2,3, 6 hours post dose and morning doses from 24h and 48h to compute.
| mg*h/L | Phase 2: 300 mg Galunisertib + Gemcitabine |
|---|---|
| Phase 2: Population Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Time Zero to 24 Hours (AUC[0-24]) | 5.56 (3.82 to 7.91) |
Plasma samples for pharmacokinetic (PK) analysis were obtained on Day 14 at 0 hours (Pre-dose), 0.5, 2, 3, 6 hours post dose and morning doses from 24h and 48h. Cmax takes all time points post dose into account and one value is reported.
| ng/mL | Phase 2: 300 mg Galunisertib + Gemcitabine |
|---|---|
| Phase 2: Population PK: Maximum Concentration (Cmax) of Galunisertib | 904 (668 to 1194) |
The BPI-SF Pain Severity Subscale was a participant-rated questionnaire that measured the severity of pain. Severity scores could have ranged from 0 (no pain) to 10 (pain as bad as you can imagine) for questions that included assessing average pain in the past 24 hours.
| Units on a scale | Phase 2: 300 mg Galunisertib + Gemcitabine | Placebo+Gemcitabine |
|---|---|---|
| Phase 2: Change From Baseline in Brief Pain Inventory-short Form (BPI-sf) at Study Completion | 2.54 ± 2.53 | 1.50 ± 2.12 |
Carbohydrate antigen 19-9 (CA 19-9) is a modified Lewis(a) blood group antigen, and has been used as a tumor marker. The outcome measure is the median, minimum and maximum values from participants who had samples collected at baseline and at follow-up
| Units/Milliliter (U/mL) | Phase 2: 300 mg Galunisertib + Gemcitabine | Phase 2: Placebo + Gemcitabine |
|---|---|---|
| Phase 2: Change From Baseline in Carbohydrate Antigen 19.9 (CA19-9) Level at First Study Completion Follow-up | 32.7 (-93.8 to 3636.3) | -33.3 (-98.1 to 2460.9) |
Collected over Up to 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1b: 80 mg Galunisertib + Gemcitabine | — | 1/5 (20%) | 5/5 (100%) |
| Phase 1b: 160 mg Galunisertib + Gemcitabine | — | 1/4 (25%) | 4/4 (100%) |
| Phase 1b: 300 mg Galunisertib + Gemcitabine | — | 2/5 (40%) | 5/5 (100%) |
| Phase 2: 300 mg Galunisertib + Gemcitabine | — | 56/103 (54.4%) | 100/103 (97.1%) |
| Phase 2: Placebo + Gemcitabine | — | 26/52 (50%) | 49/52 (94.2%) |
| Event | Phase 1b: 80 mg Galunisertib + Gemcitabine | Phase 1b: 160 mg Galunisertib + Gemcitabine | Phase 1b: 300 mg Galunisertib + Gemcitabine | Phase 2: 300 mg Galunisertib + Gemcitabine | Phase 2: Placebo + Gemcitabine |
|---|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/5 | 1/4 | 0/5 | 5/103 | 1/52 |
| Large intestinal obstructionGastrointestinal disorders | 1/5 | 0/4 | 0/5 | 0/103 | 0/52 |
| PyrexiaGeneral disorders | 0/5 | 0/4 | 1/5 | 4/103 | 3/52 |
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 0/5 | 0/4 | 1/5 | 0/103 | 0/52 |
| Malignant ascitesNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/5 | 0/4 | 0/5 | 0/103 | 0/52 |
| Intestinal obstructionGastrointestinal disorders | 0/5 | 0/4 | 0/5 | 1/103 | 3/52 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/5 | 0/4 | 0/5 | 5/103 | 1/52 |
| VomitingGastrointestinal disorders | 0/5 | 0/4 | 0/5 | 4/103 | 2/52 |
| CholangitisHepatobiliary disorders | 0/5 | 0/4 | 0/5 | 4/103 | 2/52 |
| NauseaGastrointestinal disorders | 0/5 | 0/4 | 0/5 | 2/103 | 2/52 |
| Event | Phase 1b: 80 mg Galunisertib + Gemcitabine | Phase 1b: 160 mg Galunisertib + Gemcitabine | Phase 1b: 300 mg Galunisertib + Gemcitabine | Phase 2: 300 mg Galunisertib + Gemcitabine | Phase 2: Placebo + Gemcitabine |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 2/5 | 4/4 | 4/5 | 39/103 | 17/52 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/5 | 1/4 | 1/5 | 29/103 | 13/52 |
| AnaemiaBlood and lymphatic system disorders | 3/5 | 3/4 | 3/5 | 44/103 | 28/52 |
| VomitingGastrointestinal disorders | 3/5 | 3/4 | 3/5 | 27/103 | 19/52 |
| PyrexiaGeneral disorders | 1/5 | 3/4 | 2/5 | 38/103 | 11/52 |
| NeutropeniaBlood and lymphatic system disorders | 3/5 | 2/4 | 3/5 | 34/103 | 17/52 |
| AstheniaGeneral disorders | 0/5 | 1/4 | 3/5 | 36/103 | 17/52 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 3/5 | 1/4 | 1/5 | 4/103 | 1/52 |
| HeadacheNervous system disorders | 3/5 | 1/4 | 1/5 | 6/103 | 6/52 |
| ConstipationGastrointestinal disorders | 2/5 | 2/4 | 1/5 | 30/103 | 15/52 |
All participants who received at least one dose of study drug.
| Age, Continuous(Years) | Phase 1b: 80 mg Galunisertib + Gemcitabine | Phase 1b: 160 mg Galunisertib + Gemcitabine | Phase 1b: 300 mg Galunisertib + Gemcitabine | Phase 2: 300 mg Galunisertib + Gemcitabine | Phase 2: Placebo + Gemcitabine | Total |
|---|---|---|---|---|---|---|
| Mean | 63.2 ± 12.9 | 63.8 ± 9.0 | 56.6 ± 9.2 | 67.3 ± 8.2 | 66.3 ± 8.9 | 63.5 ± 9.7 |
| Sex: Female, Male(Participants) | Phase 1b: 80 mg Galunisertib + Gemcitabine | Phase 1b: 160 mg Galunisertib + Gemcitabine | Phase 1b: 300 mg Galunisertib + Gemcitabine | Phase 2: 300 mg Galunisertib + Gemcitabine | Phase 2: Placebo + Gemcitabine | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 3 | 3 | 46 | 24 | 76 |
| Male | 5 | 1 | 2 | 57 | 28 | 93 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1b: 80 mg Galunisertib + Gemcitabine | Phase 1b: 160 mg Galunisertib + Gemcitabine | Phase 1b: 300 mg Galunisertib + Gemcitabine | Phase 2: 300 mg Galunisertib + Gemcitabine | Phase 2: Placebo + Gemcitabine | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 0 | 0 | 1 |
| Not Hispanic or Latino | 5 | 4 | 4 | 37 | 18 | 68 |
| Unknown or Not Reported | 0 | 0 | 0 | 66 | 34 | 100 |
| Race (NIH/OMB)(Participants) | Phase 1b: 80 mg Galunisertib + Gemcitabine | Phase 1b: 160 mg Galunisertib + Gemcitabine | Phase 1b: 300 mg Galunisertib + Gemcitabine | Phase 2: 300 mg Galunisertib + Gemcitabine | Phase 2: Placebo + Gemcitabine | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 0 | 0 | 0 | 2 |
| White | 3 | 4 | 5 | 95 | 50 | 157 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 8 | 2 | 10 |
| Region of Enrollment(Participants) | Phase 1b: 80 mg Galunisertib + Gemcitabine | Phase 1b: 160 mg Galunisertib + Gemcitabine | Phase 1b: 300 mg Galunisertib + Gemcitabine | Phase 2: 300 mg Galunisertib + Gemcitabine | Phase 2: Placebo + Gemcitabine | Total |
|---|---|---|---|---|---|---|
| Belgium | 0 | 0 | 0 | 4 | 2 | 6 |
| United States | 5 | 2 | 1 | 7 | 4 | 19 |
| Italy | 0 | 0 | 0 | 23 | 10 | 33 |
| France | 0 | 0 | 0 | 21 | 9 | 30 |
| Germany | 0 | 0 | 0 | 22 | 14 | 36 |
| Spain | 0 | 2 | 4 | 26 | 13 | 45 |
The record gives a start of Jun 2011, a primary completion of Nov 2015 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.
Results were first posted in May 2018, 2 years 6 months after primary completion. A results delay was requested in Dec 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LY-2157299